HOME >> BIOLOGY >> NEWS
Yale scientists visualize details of how hepatitis C unwinds RNA

New Haven, Conn. -- Research led by Anna Marie Pyle, professor of molecular biophysics and biochemistry at Yale University reveals how a protein from Hepatitis C (HCV) unwinds RNA, potentially allowing it to be copied.

The work published in the journal Nature focuses on an enzyme, helicase NS3, that unwinds the RNA virus for replication inside cells. NS3 is one member of an extensive family of helicases and is used as a model for studying unwinding activities of motor proteins.

Their findings are particularly important because NS3 is a major drug target against HCV and understanding the helicase function will aid in the development of HCV inhibitors.

Pyle's results contradict the idea that helicases move smoothly with the continuous action of a snow plow. Instead, NS3 moves with a discontinuous stepping motion that alternates rapid translocation with pausing. "We observe that the helicase proceeds through discreet spatial and kinetic microstates," Pyle said. "We actually track the speed and processivity of the helicase as it passes through each base pair of its substrate."

"While this report is the first of its kind, and has produced highly significant results, it is only the beginning of a new understanding in HCV enzymology," said Pyle. "In the future, our approaches will be used to understand the composition of the HCV replication complex and the interplay between its constituent proteins. Comparative studies will be done on other viruses and in other systems where helicase function is critical."

These novel features were revealed using a new type of combinatorial enzymology that allows the behavior of helicase enzymes to be directly compared on a sequence panel. This is the first time that the behavior of a nucleic acid remodeling protein has been monitored at this high resolution, as it acts upon or passes each subunit of its target, according to Pyle. Since the work was conducted on RNA, it helps to b
'"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203- 432-2157
Yale University
23-Jul-2004


Page: 1 2

Related biology news :

1. DNA lends scientists a hand, revealing new chemical reactions
2. Conference at UH opens doors for new scientists, engineers
3. Wisconsin scientists develop quick botox test
4. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
5. Alaska scientists find Arctic tundra yields surprising carbon loss
6. UAF scientists discover new marine habitat in Alaska
7. Information system to help scientists analyze mechanisms of social behavior
8. Zoonotic diseases - European scientists unite to fight diseases
9. Israeli scientists reveal the plan of a key cellular machine
10. Study by Israeli scientists provides insight on DNA code
11. Computer scientists at UH developing nurturing computers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Yale scientists visualize details how hepatitis unwinds RNA

(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
(Date:11/4/2014)... majority of Madagascar,s 101 species of lemurs are threatened ... the rainforests they call home. A new study by ... have on rainforest tree populations, which raises concerns about ... region,s rich biodiversity. , A large proportion of trees ... Lemurs in turn disperse the seeds of their fruit ...
(Date:11/3/2014)... report that low birth weight and preterm birth are ... in adulthood. Findings published in the American College of ... indicate that low birth weight and pre-term babies were ... OA as adults. , According to the ACR, ... diagnosed with clinical OA. Symptoms of OA range from ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
(Date:11/21/2014)... (PRWEB) November 20, 2014 Offering a ... Sartorius Entris Balance promotion . The Sartorius Entris ... a durable, high accuracy, and easy-to-maintain balance entry level ... Germany. It was designed to help customer’s bridge the ... a balance that is very durable. Sartorius is the ...
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
Breaking Biology Technology:Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: